Scott Schoenhaus
Stock Analyst at Keybanc
(1.93)
# 2,923
Out of 4,783 analysts
92
Total ratings
35.44%
Success rate
-8.55%
Average return
Main Sectors:
Stocks Rated by Scott Schoenhaus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HQY HealthEquity | Maintains: Overweight | $120 → $110 | $88.83 | +23.83% | 4 | Mar 24, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $25 → $27 | $20.27 | +33.20% | 4 | Jan 24, 2025 | |
| VEEV Veeva Systems | Maintains: Overweight | $285 → $255 | $237.48 | +7.38% | 15 | Jan 8, 2025 | |
| SLP Simulations Plus | Maintains: Overweight | $40 → $35 | $24.22 | +44.51% | 2 | Jan 8, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Overweight | $12 → $10 | $5.97 | +67.50% | 6 | Jan 8, 2025 | |
| PHR Phreesia | Maintains: Overweight | $28 → $30 | $27.17 | +10.42% | 6 | Jan 8, 2025 | |
| ODD Oddity Tech | Maintains: Overweight | $50 → $52 | $43.60 | +19.27% | 2 | Jan 8, 2025 | |
| LFMD LifeMD | Maintains: Overweight | $10 → $7 | $5.60 | +25.00% | 3 | Jan 8, 2025 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $7 → $6 | $4.52 | +32.74% | 5 | Jan 8, 2025 | |
| DOCS Doximity | Maintains: Overweight | $70 → $65 | $60.55 | +7.35% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.81 | +77.94% | 5 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.36 | +69.49% | 4 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 | $4.60 | +95.65% | 5 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $2.66 | +69.17% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $11 | $6.21 | +77.13% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $10.12 | +97.63% | 3 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $22.31 | - | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $35.35 | - | 8 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Weight | n/a | $8.56 | - | 4 | Sep 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $180 → $250 | $179.36 | +39.38% | 2 | Apr 16, 2021 |
HealthEquity
Mar 24, 2025
Maintains: Overweight
Price Target: $120 → $110
Current: $88.83
Upside: +23.83%
Schrödinger
Jan 24, 2025
Maintains: Overweight
Price Target: $25 → $27
Current: $20.27
Upside: +33.20%
Veeva Systems
Jan 8, 2025
Maintains: Overweight
Price Target: $285 → $255
Current: $237.48
Upside: +7.38%
Simulations Plus
Jan 8, 2025
Maintains: Overweight
Price Target: $40 → $35
Current: $24.22
Upside: +44.51%
Recursion Pharmaceuticals
Jan 8, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $5.97
Upside: +67.50%
Phreesia
Jan 8, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $27.17
Upside: +10.42%
Oddity Tech
Jan 8, 2025
Maintains: Overweight
Price Target: $50 → $52
Current: $43.60
Upside: +19.27%
LifeMD
Jan 8, 2025
Maintains: Overweight
Price Target: $10 → $7
Current: $5.60
Upside: +25.00%
GoodRx Holdings
Jan 8, 2025
Maintains: Overweight
Price Target: $7 → $6
Current: $4.52
Upside: +32.74%
Doximity
Jan 8, 2025
Maintains: Overweight
Price Target: $70 → $65
Current: $60.55
Upside: +7.35%
Jan 8, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $2.81
Upside: +77.94%
Jan 8, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.36
Upside: +69.49%
Jan 8, 2025
Upgrades: Overweight
Price Target: $9
Current: $4.60
Upside: +95.65%
Dec 9, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.66
Upside: +69.17%
Nov 13, 2024
Maintains: Overweight
Price Target: $10 → $11
Current: $6.21
Upside: +77.13%
Jul 11, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $10.12
Upside: +97.63%
May 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $22.31
Upside: -
Oct 11, 2023
Downgrades: Sector Weight
Price Target: n/a
Current: $35.35
Upside: -
Sep 16, 2022
Initiates: Sector Weight
Price Target: n/a
Current: $8.56
Upside: -
Apr 16, 2021
Upgrades: Overweight
Price Target: $180 → $250
Current: $179.36
Upside: +39.38%